Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

2.41USD
18 Aug 2017
Change (% chg)

$0.39 (+19.31%)
Prev Close
$2.02
Open
$2.02
Day's High
$2.50
Day's Low
$2.00
Volume
203,274
Avg. Vol
72,755
52-wk High
$18.15
52-wk Low
$1.86

AMRS.OQ

Chart for AMRS.OQ

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $75.97
Shares Outstanding(Mil.): 37.61
Dividend: --
Yield (%): --

Financials

  AMRS.OQ Industry Sector
P/E (TTM): -- 19.11 43.64
EPS (TTM): -6.24 -- --
ROI: -835.10 7.39 9.36
ROE: -- 9.46 12.04

BRIEF-Amyris Q2 loss per share $0.46

* Amyris delivers another strong quarter with revenue of $25.7 million and product sales increase of 159% over 2nd quarter of 2016

Aug 10 2017

BRIEF-Vivo Capital VIII reports 9.9 pct stake in Amyris

* Vivo Capital VIII LLC reports 9.9 percent passive stake in Amyris Inc as of August 2, 2017 - SEC filing Source text: (http://bit.ly/2vCkff7) Further company coverage:

Aug 08 2017

BRIEF-Amyris files for offer and sale of up to 42.27 mln shares

* Amyris Inc files for offer and sale of up to 42.27 million shares of co's common stock by the selling stockholders - sec filing‍​ Source text: (http://bit.ly/2hwaLw0) Further company coverage:

Aug 04 2017

BRIEF-Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​

* Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million

Aug 03 2017

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

Jul 17 2017

BRIEF-Amyris, on June 30, 2017, company issued, sold an amended, restated note in principal amount of $3 mln to purchaser

* Amyris Inc - on June 30, 2017, company issued and sold an amended and restated note in principal amount of $3.0 million to purchaser - sec filing

Jul 07 2017

BRIEF-Amyris and government of Queensland announced plans to develop a industrial biotechnology hub in Southeast Asia

* Amyris Inc and government of Queensland, Australia announced plans to develop a industrial biotechnology hub in Southeast Asia Source text for Eikon: Further company coverage:

Jun 20 2017

BRIEF-Amyris announces reverse stock split

* Amyris announces reverse stock split - delivering on strong product revenue growth and execution

Jun 06 2017

BRIEF-Amyris reports Q1 loss per share of $0.13

* Amyris reports 164 pct product revenue growth over prior year & continued strong outlook

May 15 2017

BRIEF-Amyris on-track to double revenue for vitamin e partnership

* Amyris on-track to double revenue for vitamin e partnership with nenter & announces exclusive vitamin a license with royal DSM

May 10 2017

Earnings vs. Estimates